Summit Therapeutics (SMMT) Cash & Equivalents (2017 - 2026)

Summit Therapeutics (SMMT) has 10 years of Cash & Equivalents data on file, last reported at $419.4 million in Q2 2026.

• Quarterly Cash & Equivalents rose 40.79% year-over-year to $419.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $419.4 million (up 40.79% YoY) and the FY2025 annual result came in at $225.3 million, up 114.82% from the prior year.
• Cash & Equivalents advanced to $419.4 million in Q2 2026, from $106.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $419.4 million in Q2 2026 to a low of $23.8 million in Q3 2023.
• A 5-year average of $154.1 million and a median of $105.7 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 80.49% — and 2025, when it surged 947.59%.
• Tracing SMMT's Cash & Equivalents over 5 years: stood at $348.6 million in 2022, then slumped by 79.51% to $71.4 million in 2023, then soared by 46.81% to $104.9 million in 2024, then surged by 114.82% to $225.3 million in 2025, then jumped by 86.16% to $419.4 million in 2026.
• The last three Cash & Equivalents figures came in at $419.4 million (Q2 2026), $106.5 million (Q1 2026), and $225.3 million (Q4 2025), per Business Quant data.